NetworkNewsBreaks – Heron Therapeutics, Inc. (NASDAQ: HRTX) – Financials Outweigh Positive HTX-011 Data
Shares of Heron Therapeutics (NASDAQ: HRTX) tumbled from yesterday’s rally after its Q4 Sustol sales results and FY2017 guidance overshadowed separately reported data from phase 2 studies of HTX-011 in patients undergoing bunionectomy (Study 208) and abdominoplasty (Study 203). In a filing, Heron reported Q4 sales of Sustol at $1.1 million and full-year sales of $15 million-$25 million, short of analyst estimates for $2.1 million and $48.8 million, respectively. Regarding the studies: Heron said the results of Study 208 demonstrate statistically significant synergy between the local anesthetic bupivacaine and the anti-inflammatory meloxicam in HTX-011, an extended-release combination product for the…